EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Scoliosis development in 5q-spinal muscular atrophy under disease modifying therapies

Tu-Lan Vu-Han, Claudia Weiß, Paul Köhli, Lukas Schönnagel, Carsten Perka, Matthias Pumberger

European Spine Journal · 2025

DOI: 10.1007/s00586-024-08586-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Spine Journal, 2025. Verfasst von Tu-Lan Vu-Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Musculoskeletal Surgery (CMSC), Charité Universitätsmedizin, Campus Mitte Charitéplatz 1, Berlin, Germany. tu-lan.vu-han@charite.de. Hauptthemen laut MEDLINE: Scoliosis, Spinal Muscular Atrophies of Childhood, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Berlin Institute of Health, Charité - Universitätsmedizin Berlin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

5q-spinal muscular atrophy (SMA) is a treatable neuromuscular disorder associated with scoliosis in up to 90% of patients. New SMA therapies could mark a paradigm shift in scoliosis management, but their effects on scoliosis development remain unclear. This study aims to observe scoliosis progression in the current treatment landscape to inform management strategies.

Methods

We conducted a cross-sectional retrospective analysis of 94 SMA patients treated at our center. Scoliosis development was evaluated in 75 patients using spine radiographs and electronic health records. Statistical analysis was performed using Python and GraphPad Prism. One-way ANOVA and Pearson correlation were used for group comparisons and correlation analysis, respectively.

Results

Scoliosis parameters in 5q-SMA patients who had received either nusinersen, onasemnogene abeparvovec, risdiplam, or their combinations showed mean ages at scoliosis detection were 23.94, 55.52, and 168.11 months for SMA types 1, 2, and 3, respectively. Cobb angles at detection showed no significant intergroup differences. The mean ages at scoliosis surgery were 60, 88.43, and 124.8 months. Pelvic obliquity (PO) was highest in type 1 and lowest in type 3. A strong correlation (r = 0.9) was found between PO measurement techniques. HFMSE scores correlated moderately with scoliosis severity (r = -0.38), while CHOP-INTEND showed no correlation.

Conclusion

The observations made in this study suggest that the effects of SMA therapies do not prevent scoliosis development. The improved prognosis may lead to a growing cohort of SMA type 1 and 2 patients with early onset scoliosis who require early growth-friendly surgical interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ScoliosisSpinal Muscular Atrophies of ChildhoodMuscular Atrophy, SpinalHumansMaleFemaleRetrospective StudiesCross-Sectional StudiesChildChild, PreschoolOligonucleotidesDisease ProgressionBiological ProductsAzo CompoundsPyrimidines

Stichwörter der Autor:innen

Gene therapyNeuromuscular scoliosisPediatric deformityRare disease

Substanzen

nusinersenOligonucleotidesRisdiplamBiological ProductsAzo CompoundsPyrimidines

Autor:innen und Institutionen

  • Center for Musculoskeletal Surgery (CMSC), Charité Universitätsmedizin, Campus Mitte Charitéplatz 1, Berlin, Germany. tu-lan.vu-han@charite.de.
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Digital Clinician Scientist Program, Charitéplatz 1, 10117, Berlin, Germany. tu-lan.vu-han@charite.de.
  • Explainable AI for Biology, Zuse Institute Berlin, Takustraße 7, 14195, Berlin, Germany. tu-lan.vu-han@charite.de.
  • Department of Pediatric Neurology, Center for Chronically Sick Children, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, Germany.
  • Center for Musculoskeletal Surgery (CMSC), Charité Universitätsmedizin, Campus Mitte Charitéplatz 1, Berlin, Germany.
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Digital Clinician Scientist Program, Charitéplatz 1, 10117, Berlin, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft
  • Berlin Institute of Health
  • Charité - Universitätsmedizin Berlin

Zitieren

APA

Vu-Han, T. L., Weiß, C., Köhli, P., Schönnagel, L., Perka, C., & Pumberger, M. (2025). Scoliosis development in 5q-spinal muscular atrophy under disease modifying therapies. European Spine Journal. https://doi.org/10.1007/s00586-024-08586-y

Vancouver

Vu-Han TL, Weiß C, Köhli P, Schönnagel L, Perka C, Pumberger M. Scoliosis development in 5q-spinal muscular atrophy under disease modifying therapies. European Spine Journal. 2025. doi:10.1007/s00586-024-08586-y

BibTeX
@article{VuHan2025,
  author = {Vu-Han, Tu-Lan and Weiß, Claudia and Köhli, Paul and Schönnagel, Lukas and Perka, Carsten and Pumberger, Matthias},
  title = {Scoliosis development in 5q-spinal muscular atrophy under disease modifying therapies},
  journal = {European Spine Journal},
  year = {2025},
  doi = {10.1007/s00586-024-08586-y}
}
Kostenlos starten →